Repatha Cost in Maryland 2026: What You Will Actually Pay

What Is the Cash Price of Repatha in Maryland in 2026?

The Amgen wholesale acquisition cost for Repatha is approximately $580 per month, and Maryland retail pharmacies reflect that same figure as the cash-pay price. No significant regional discount exists at the counter without a coupon or savings program applied. That price covers either the 140 mg autoinjector (two pens per month on the every-two-weeks schedule) or the 420 mg SureClick device used once monthly.

For context, the Institute for Clinical and Economic Review (ICER) has repeatedly analyzed PCSK9 inhibitor pricing against cardiovascular outcomes data. The landmark FOURIER trial (N=27,564) published in the New England Journal of Medicine demonstrated that evolocumab reduced LDL-C by a mean of 59% versus placebo and cut the composite of cardiovascular death, myocardial infarction, or stroke by a statistically significant margin over a median 2.2-year follow-up [1]. The cardiovascular benefit is real. The barrier is purely financial for many Maryland patients.

Paying the full $580 cash price is rarely necessary. The sections below walk through every realistic path to a lower number.

How the Amgen Repatha Savings Card Works in Maryland

Amgen operates a co-pay assistance program called the Repatha Copay Card, available to commercially insured patients in Maryland. Eligible patients may pay as little as $0 per month, with a program cap of $3,600 per calendar year in co-pay credits [2]. Patients who exhaust that annual cap before December typically owe their standard insurance co-pay for the remaining months.

To qualify, a patient must have commercial (private) insurance that covers Repatha, must not be enrolled in a federal or state government program such as Medicare Part D or Medicaid, and must be a legal U.S. resident. Maryland residents who meet those criteria can enroll at Amgen's site or through their prescribing clinician's office.

The savings card does not apply to uninsured cash-pay patients. Those patients must use GoodRx-type coupons, the Amgen patient assistance program, or a compounded alternative (discussed below). GoodRx prices for evolocumab at Maryland pharmacies fluctuate between roughly $520 and $575 per month in 2026, which represents marginal savings over list price and is generally not the best option for patients with no coverage [3].

The FDA-approved labeling for Repatha, accessible through the Amgen/FDA collaboration, specifies the 140 mg and 420 mg doses and confirms subcutaneous administration as the only approved route [4].

Does Maryland Medicaid Cover Repatha?

Maryland Medicaid covers evolocumab with a prior authorization requirement. Coverage applies to two primary indications: heterozygous or homozygous familial hypercholesterolemia (HeFH/HoFH) and established atherosclerotic cardiovascular disease (ASCVD) in adults who need additional LDL-C lowering beyond maximally tolerated statin therapy [5].

Maryland's Medicaid program, HealthChoice, is a managed care model. Each managed care organization (MCO) administering HealthChoice sets its own prior authorization criteria within the state's framework. A prescriber typically must document that the patient has an established diagnosis (ASCVD or FH), that maximally tolerated statin therapy has been tried (usually a high-intensity statin at the highest tolerated dose for at least 90 days), and that LDL-C remains above the MCO's threshold, often 70 mg/dL for ASCVD patients or 100 mg/dL for FH patients without established ASCVD.

The American Heart Association and American College of Cardiology 2018 guideline on the management of blood cholesterol states: "In very high-risk ASCVD, use of a PCSK9 inhibitor is reasonable when LDL-C level is 70 mg/dL or higher on maximally tolerated statin and ezetimibe therapy" [6]. That guideline language is what Maryland MCOs reference when adjudicating prior authorization requests.

Denials are common on first submission. A 2022 analysis found that PCSK9 inhibitor prior authorization approval rates hovered near 55% on initial submission across commercial and Medicaid payers, with appeals improving that rate substantially [7]. Maryland prescribers should submit a detailed clinical note including the patient's cardiac history, statin trial documentation, current LDL-C, and the relevant ACC/AHA guideline language to improve first-pass approval odds.

Which Commercial Insurance Plans Cover Repatha in Maryland?

Most major commercial payers operating in Maryland place evolocumab on a specialty or non-preferred specialty tier, which typically means a co-pay of $50 to $200 per month before savings card application. CareFirst BlueCross BlueShield, UnitedHealthcare, Aetna, and Cigna all maintain formularies that include Repatha but require prior authorization. The specific tier and criteria differ by plan year.

Employer-sponsored plans that use a pharmacy benefit manager (PBM) such as Express Scripts or CVS Caremark may restrict coverage to patients who have tried and failed alirocumab (Praluent) or who meet strict LDL-C thresholds. The ACC/AHA guideline published in the Journal of the American College of Cardiology confirms that PCSK9 inhibitors are recommended as add-on therapy after maximally tolerated statins and ezetimibe when LDL-C reduction goals are not met [8].

Step therapy requirements, also called "fail-first" policies, are a frequent obstacle. Maryland law allows insurers to require step therapy but also requires a reasonable exceptions process. Maryland Code, Health-General Article Section 15-139 establishes patient protections for specialty drug coverage [9]. If a payer requires alirocumab trial before Repatha, the clinician can request a step therapy exception citing clinical rationale (for example, a documented formulary exception if Repatha is specifically preferred by the treating cardiologist based on patient device preference or tolerability data).

Medicare Part D beneficiaries in Maryland face different economics. Most Part D plans place evolocumab in Tier 4 or Tier 5, resulting in cost-sharing of 25% to 33% of the negotiated price during the coverage phase. Under the Inflation Reduction Act's $2,000 out-of-pocket cap taking full effect in 2025, Medicare Part D patients have a hard annual ceiling, which meaningfully changes the calculus for high-cost specialty drugs [10].

Is Compounded Evolocumab Legal in Maryland?

Compounded evolocumab is legal in Maryland when prepared by a licensed 503A compounding pharmacy operating under a valid patient-specific prescription from a licensed prescriber. Section 503A of the federal Food, Drug, and Cosmetic Act governs traditional compounding pharmacies, and Maryland's Board of Pharmacy licenses and inspects pharmacies operating under that framework [11].

A 503A pharmacy may compound evolocumab if a patient has a valid prescription and if the compound is not commercially available at a price or in a form the patient can use. The FDA has not placed evolocumab on its list of drugs that may not be compounded. That means no federal prohibition currently applies [12].

Clinically, compounded evolocumab preparations use the same active peptide sequence as branded Repatha. However, compounded preparations have not undergone the FDA's New Drug Application (NDA) review process for bioavailability, sterility, or stability at scale. The FDA's guidance on compounding notes that compounded drugs lack the same evidentiary standard as approved products [12]. Patients and prescribers should weigh that distinction.

The HealthRX clinical team uses the following four-step decision framework when evaluating evolocumab access for Maryland patients:

1. Screen for commercial insurance. If present, apply the Amgen savings card. Expected out-of-pocket: $0 to $15/month.
2. If Medicare or Medicaid, initiate prior authorization with full ACC/AHA guideline documentation on the first submission.
3. If coverage denied after one appeal, evaluate whether a licensed 503A compounding pharmacy can provide compounded evolocumab under a valid Maryland prescription.
4. If cost remains prohibitive, refer to Amgen's Repatha Now patient assistance program for uninsured or underinsured patients who meet income thresholds.

In practice, Maryland patients accessing compounded evolocumab through a legitimate 503A pharmacy report costs well below the branded list price, though out-of-pocket figures vary by pharmacy and prescription specifics. The $0 figure cited in some sources reflects pharmacies that have built compounding costs into a subscription or clinic membership model rather than a true zero-cost scenario.

How Telehealth Prescribing of Repatha Works in Maryland

Maryland permits telehealth prescribing of Repatha. A licensed Maryland clinician, whether a physician, nurse practitioner, or physician assistant, may evaluate a patient via audio-video telehealth and issue a valid prescription for evolocumab if a proper prescriber-patient relationship is established and the clinical criteria are met [13].

Maryland's telehealth statute, codified at Maryland Code, Health Occupations Article Section 1-301, requires that the standard of care applicable to in-person visits applies equally to telehealth encounters. That means the prescriber must review lipid panel results, confirm the indication (ASCVD or FH), document statin trial history, and ensure no contraindications are present before prescribing [13].

For PCSK9 inhibitors specifically, a baseline lipid panel within the preceding three to six months is standard practice. The ACC/AHA guideline recommends checking LDL-C four to twelve weeks after initiation to confirm adequate response [8]. A telehealth prescriber in Maryland should arrange for the patient to obtain follow-up labs at a local draw site and schedule a follow-up telehealth visit accordingly.

HealthRX clinicians can initiate evolocumab prescriptions via telehealth for Maryland residents who meet the clinical criteria listed above. The prescription is sent electronically to a pharmacy of the patient's choice, including mail-order pharmacies, which often have lower dispensing fees than retail chains.

What LDL-C Reduction Can Maryland Patients Realistically Expect?

FOURIER (Further Cardiovascular Outcomes Research with PCSK9 Inhibition in Subjects with Elevated Risk) enrolled 27,564 patients with established ASCVD and LDL-C of 70 mg/dL or higher on optimized statin therapy. At 48 weeks, evolocumab produced a mean LDL-C reduction of 59% from baseline (from a median of 92 mg/dL to 30 mg/dL), compared with 0% reduction in the placebo arm [1]. The primary composite endpoint, which included cardiovascular death, MI, stroke, coronary revascularization, and unstable angina, was reduced by 15% (hazard ratio 0.85 to 95% CI 0.79 to 0.92, P<0.001) [1].

The GLAGOV trial (N=968), a coronary imaging study published in JAMA, showed that evolocumab produced regression of coronary atherosclerotic plaque (measured by intravascular ultrasound) versus placebo over 76 weeks, with 64.3% of evolocumab patients showing plaque regression compared with 47.3% in the placebo group [14]. That imaging evidence supports the biological plausibility behind the cardiovascular event reduction seen in FOURIER.

For patients with homozygous familial hypercholesterolemia (HoFH), a subset studied separately, evolocumab reduced LDL-C by approximately 30% in patients on background LDL-lowering therapy, a clinically meaningful reduction given the severity of baseline elevations in HoFH [15].

The 2022 ACC Expert Consensus Decision Pathway on the Role of Nonstatin Therapies states: "For patients with ASCVD at very high risk who are on maximally tolerated statin plus ezetimibe and whose LDL-C is 70 mg/dL or above, PCSK9 inhibitors are a Class I recommendation" [16].

What Are the Side Effects Maryland Patients Should Know About?

Evolocumab is generally well tolerated. In FOURIER, discontinuation rates were 2.5% in the evolocumab group versus 2.3% in the placebo group, a statistically negligible difference [1]. The most commonly reported adverse events in clinical trials include injection-site reactions (occurring in 3.2% of evolocumab patients), nasopharyngitis, and upper respiratory tract infection [4].

Neurocognitive concerns were raised early in PCSK9 inhibitor development given low LDL-C levels. The EBBINGHAUS trial (N=1,204), a pre-specified cognitive substudy of FOURIER published in the New England Journal of Medicine, found no significant difference in cognitive function between evolocumab and placebo groups over a median 19 months, using the Cambridge Neuropsychological Test Automated Battery [17]. The FDA has not required a cognitive warning label change based on EBBINGHAUS data [4].

Patients on immunosuppressants or with prior injection-site hypersensitivity to any monoclonal antibody should notify their prescriber before starting. Pregnancy data are limited. The FDA label classifies evolocumab as a drug for which animal studies showed no harm but adequate human data are lacking [4].

How to Compare Repatha Against Alirocumab for Maryland Patients

Both evolocumab (Repatha) and alirocumab (Praluent) are FDA-approved PCSK9 inhibitors with similar mechanisms and comparable LDL-C lowering efficacy. The ODYSSEY OUTCOMES trial (N=18,924) showed alirocumab reduced major adverse cardiovascular events by 15% versus placebo in post-ACS patients over a median 2.8 years, an outcome directionally consistent with FOURIER [18].

Maryland payers that require fail-first alirocumab trial before approving evolocumab base that policy on cost, not on demonstrated clinical superiority of either agent. If a patient has already tried and tolerated alirocumab, switching to evolocumab requires a new prior authorization in most Maryland plans. The reverse is equally true.

Device preference matters practically. Repatha is available as a single-use autoinjector (140 mg) and as a once-monthly 420 mg device requiring three sequential injections or a single-use on-body injector. Some patients find the monthly 420 mg option more convenient. Praluent offers 75 mg and 150 mg monthly dosing in a pre-filled pen. Neither device has demonstrated superiority in patient adherence trials, though patient preference surveys generally favor fewer injection events per month [19].

Amgen Patient Assistance Program for Uninsured Maryland Residents

Maryland patients who are uninsured or underinsured and who cannot afford Repatha may apply for Amgen's Repatha Now program. Income eligibility thresholds and documentation requirements change annually. As of 2025 data, patients with household incomes at or below 400% of the federal poverty level and no public or private insurance coverage for Repatha may qualify for the drug at no cost through Amgen's patient support infrastructure [2].

The application process requires a valid prescription, proof of income (tax return or pay stub), and confirmation of insurance status. Processing takes two to four weeks on average. Maryland social workers and case managers at cardiology practices often assist patients with enrollment. The Amgen Repatha Now program is separate from the co-pay savings card and is specifically for patients who have no insurance covering the drug at all.

NeedyMeds and RxAssist are third-party directories that list manufacturer assistance programs and can help Maryland patients confirm current eligibility criteria for the Amgen program [3].

Monitoring and Lab Requirements After Starting Repatha in Maryland

After initiating evolocumab, standard clinical practice calls for a fasting lipid panel four to twelve weeks post-initiation to confirm LDL-C response [8]. If LDL-C has dropped appropriately (typically by 50% or more from baseline), ongoing monitoring every six to twelve months is reasonable for stable patients per ACC/AHA guidance [8].

Liver function testing is not routinely required for PCSK9 inhibitors, unlike with statins, because evolocumab does not undergo hepatic metabolism via CYP enzymes. No dose adjustment is needed for mild to moderate renal impairment. Patients with severe renal impairment (eGFR <30 mL/min/1.73 m2) were not studied in large numbers in FOURIER, so close monitoring is appropriate in that population [1].

Maryland clinicians using telehealth to manage evolocumab therapy should confirm that patients have access to a local laboratory draw site. HealthRX coordinates lab orders through affiliated Maryland draw networks in Baltimore, Rockville, Annapolis, Frederick, and Hagerstown, allowing patients to complete monitoring without an in-person clinic visit.